GET DAILY SIGNALSHIVE Digital Technologies (HIVE): Can Analyst Targets Deliver +271% Upside?
Key Takeaways
- The central $6.60 stock price target is the arithmetic mean of seven verified analyst price targets reviewed for this analysis, spanning a wide $4.60 to $10.00 range.
- With shares near $1.78, reaching $6.60 would require roughly 271% upside — a very large move by any conventional standard.
- Wall Street is broadly bullish, with most firms at Buy or Overweight, but one Market Perform and one Sell/Strong Sell rating underscore sharp disagreement.
- The strongest support comes from HIVE's AI and high-performance computing (HPC) pivot, its green-energy data center footprint, and rising Bitcoin production.
- The biggest risks are persistent net losses, heavy dependence on Bitcoin prices, and dilution from at-the-market equity programs.
- For more context, explore Major News, Today's Price Move, Forecast, and Earnings pages for HIVE.
- You can also explore Trending AI Robots to see AI-driven trading strategies across the market.
Analyst Price Targets and Consensus View
HIVE Digital Technologies Ltd. (HIVE) is a stock, not an exchange-traded fund. It is a sustainable-energy-focused digital infrastructure company that operates data centers for Bitcoin mining and AI/HPC workloads, with facilities in Canada, Sweden, Paraguay, and Bermuda. Its analyst coverage remains active but divided. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
This analysis reviewed seven current price targets. Canaccord Genuity's Joseph Vafi holds the highest at $10.00 (reiterated October 2026), while Chardan Capital maintains $7.50, H.C. Wainwright $7.00, Rosenblatt Securities $6.00, B. Riley Securities $6.00, Keefe, Bruyette & Woods $5.00, and Cantor Fitzgerald $4.60. The arithmetic mean is approximately $6.59, rounded to a $6.60 central target. The low-to-high range of $4.60 to $10.00 is unusually wide, reflecting genuine disagreement about HIVE's AI transition.
Reasoning differs by firm. Bullish analysts emphasize the BUZZ HPC segment and a rapidly scaling AI data center strategy. Cautious voices, including Keefe, Bruyette & Woods' Market Perform and Wall Street Zen's Sell/Strong Sell rating, focus on valuation, Bitcoin-mining economics, and execution risk. The mean should be read as a midpoint of divergent views, not a guarantee.
Current Market Position and Path Toward the Target
As of early November 2026, HIVE trades near $1.78, with a market capitalization around $488 million and a 52-week range of $1.58 to $5.34. From $1.78, the $6.60 target implies approximately 271% upside — a very large required move, well beyond typical year-ahead appreciation.
The path would depend on two overlapping drivers: a sustained rebound in Bitcoin and meaningful conversion of HIVE's AI/HPC pipeline into recurring, high-margin revenue. HIVE mined 2,311 Bitcoin in calendar 2025 (up 31% year over year), and its fiscal second-quarter revenue rose 285% year over year to $87.3 million, even as GAAP losses persisted. Notably, the $6.60 target sits above HIVE's 52-week high, meaning the stock would need to break decisively into new territory, not merely recover lost ground.
What Could Support a Move Toward the Target
- AI and HPC expansion: The BUZZ HPC division is HIVE's clearest valuation catalyst, with management targeting a much larger annualized HPC revenue run-rate as new capacity comes online.
- Green-energy footprint: Roughly 540 MW of renewable-powered capacity across Paraguay, Canada, and Sweden supports both mining and HPC economics.
- Bitcoin production growth: Higher hashrate and output leverage HIVE to any sustained rally in cryptocurrency prices.
- Broadly positive analyst stance: Most covering firms rate the stock Buy or Overweight, signaling confidence in the strategic pivot.
What Could Prevent the Target From Being Reached
- Persistent losses: HIVE has reported GAAP net losses despite record revenue, partly due to accelerated depreciation of mining equipment.
- Bitcoin volatility: As a Bitcoin miner, HIVE's cash generation is tightly linked to digital-asset prices and network difficulty.
- Dilution: HIVE has refreshed at-the-market equity programs, which can weigh on the share price when exercised.
- Valuation and execution risk: The AI/HPC story remains early-stage, and slower-than-expected contract conversion could compress sentiment.
Technical Levels and Market Structure
HIVE sits near the low end of its $1.58 to $5.34 52-week range. The $1.58 area represents a key support level, while the June 2026 intraday high near $5.34 acts as a notable resistance level and prior peak. Because the $6.60 target lies above that prior high, reaching it would require a breakout beyond an established ceiling — a structurally demanding setup rather than a simple retracement.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may differ and do not always state their horizon explicitly. Investors should watch quarterly results and guidance (particularly HPC/AI revenue and margins), Bitcoin price trends and network difficulty, any new data-center or hosting contracts, changes to the at-the-market equity program, and analyst target revisions. FOMC rate decisions and broader risk appetite also influence speculative, Bitcoin-linked equities like HIVE.
Using AI Tools in My Analysis
In reviewing volatile names like this one, I find Tickeron's AI Daily Buy/Sell Signals helpful for tracking shifting technical patterns and generating data-driven alerts. The service monitors thousands of stocks and ETFs in real time, which can complement manual review when markets move quickly. I have used it alongside other research to stay on top of momentum changes without replacing my own judgment.
Final Assessment
The $6.60 central target — the mean of seven verified analyst price targets ranging from $4.60 to $10.00 — sits far above HIVE's price near $1.78 and implies a very large, roughly 271% move. The bull case rests on the AI/HPC transformation, green-energy capacity, and Bitcoin leverage, while the bear case centers on persistent losses, dilution, and crypto dependency. With targets spread from $4.60 to $10.00, analysts are clearly divided on magnitude even if most are constructive on direction. Reaching $6.60 would require a breakout above HIVE's 52-week high and sustained execution on the HPC strategy — an ambitious, not assured, outcome that investors should evaluate against their own risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HIVE's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for HIVE turned positive on November 06, 2026. Looking at past instances where HIVE's MACD turned positive, the stock continued to rise in 33 of 37 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HIVE's RSI Oscillator exited the oversold zone, 36 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where HIVE advanced for three days, in 211 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
HIVE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIVE as a result. In 67 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
HIVE moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HIVE crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
The 50-day moving average for HIVE moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIVE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for HIVE entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.972) is normal, around the industry mean (3.132). P/E Ratio (9.174) is within average values for comparable stocks, (6.756). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.809). Dividend Yield (0.000) settles around the average of (8.982) among similar stocks. P/S Ratio (2.169) is also within normal values, averaging (16.899).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. HIVE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIVE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of cloud networking and enterprise Wi-Fi solution
Industry InvestmentBanksBrokers
Advertisement